forty-seven patients with primary refractory , relapsed , and previously untreated , poor risk aml were entered into a phase ii study of intermediate dose ara-c ( idac ) ( 1 g/m2 i.v . over 6 hr , daily for 6 days ) with sequential mitoxantrone ( mitox ) ( 6 mg/m2 i.v . bolus 3 hr after the end of each ara-c infusion ) .
C0023467
aml
C0026259
mitox